Ionis Pharmaceuticals, Inc. (LON:0JDI)

London flag London · Delayed Price · Currency is GBP · Price in USD
73.14
+0.64 (0.88%)
At close: Oct 17, 2025
0.88%
Market Cap8.70B
Revenue (ttm)689.06M
Net Income (ttm)-195.77M
Shares Outn/a
EPS (ttm)-1.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume351
Average Volume664
Open72.69
Previous Close72.50
Day's Range72.45 - 73.68
52-Week Range24.11 - 74.20
Betan/a
RSI78.43
Earnings DateNov 5, 2025

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1989
Employees 1,069
Stock Exchange London Stock Exchange
Ticker Symbol 0JDI
Full Company Profile

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Financial numbers in USD Financial Statements

News

Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharmaceuticals Inc (IONS)

Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharmaceuticals Inc (IONS)

3 days ago - GuruFocus

Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News

Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News

3 days ago - GuruFocus

Ionis to hold third quarter 2025 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its thir...

3 days ago - Business Wire

Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)

Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)

11 days ago - GuruFocus

Ionis Pharmaceuticals, Inc. (IONS) Shareholder/Analyst Call - Slideshow

2025-10-08. The following slide deck was published by Ionis Pharmaceuticals, Inc.

11 days ago - Seeking Alpha

Needham Raises Price Target on Ionis Pharmaceuticals (IONS) to $78 | IONS Stock News

Needham Raises Price Target on Ionis Pharmaceuticals (IONS) to $78 | IONS Stock News

11 days ago - GuruFocus

Oppenheimer Raises Ionis Pharmaceuticals (IONS) Price Target to $90 | IONS Stock News

Oppenheimer Raises Ionis Pharmaceuticals (IONS) Price Target to $90 | IONS Stock News

11 days ago - GuruFocus

JP Morgan Boosts Ionis Pharmaceuticals (IONS) with Upgrade and Price Target Increase

JP Morgan Boosts Ionis Pharmaceuticals (IONS) with Upgrade and Price Target Increase

11 days ago - GuruFocus

Ionis upgraded at JP Morgan on expanding Tryngolza market, pipeline

JP Morgan upgrades Ionis Pharmaceuticals to overweight, citing Tryngolza expansion and strong pipeline. Read more here.

11 days ago - Seeking Alpha

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike

Ionis Pharmaceuticals guided to north of $5 billion in peak sales. Early Wednesday, Ionis stock was approaching a six-year high.

11 days ago - Investor's Business Daily

JP Morgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight, Raises Price Target | IONS Stock News

JP Morgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight, Raises Price Target | IONS Stock News

11 days ago - GuruFocus

JPMorgan upgrades biopharma stock to overweight on strong drug pipeline

JPMorgan foresees shares of Ionis Pharmaceuticals rising another 16% from their Tuesday close after a 170% runup in six months.

11 days ago - CNBC

HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (IONS) | IONS Stock News

HC Wainwright Reiterates Buy Rating for Ionis Pharmaceuticals (IONS) | IONS Stock News

11 days ago - GuruFocus

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on

Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more

12 days ago - CNBC Television

Watch CNBC's full interview with Ionis Pharmaceuticals CEO Brett Monia

Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more

12 days ago - CNBC

Ionis Pharmaceuticals CEO Brett Monia on the drugs they are focused on

Ionis Pharmaceuticals CEO Brett Monia joins CNBC's 'Squawk Box' to discuss RNA-targeted therapeutics, the drugs the company is focusing on, and more

12 days ago - CNBC

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term...

12 days ago - Business Wire

Ionis Pharmaceuticals (IONS): Stifel Raises Price Target to $67 | IONS Stock News

Ionis Pharmaceuticals (IONS): Stifel Raises Price Target to $67 | IONS Stock News

13 days ago - GuruFocus

Insider Sell Alert: Patrick O'neil Sells 64,664 Shares of Ionis Pharmaceuticals Inc (IONS)

Insider Sell Alert: Patrick O'neil Sells 64,664 Shares of Ionis Pharmaceuticals Inc (IONS)

17 days ago - GuruFocus

Insider Sell: Patrick O'neil Sells 25,300 Shares of Ionis Pharmaceuticals Inc (IONS)

Insider Sell: Patrick O'neil Sells 25,300 Shares of Ionis Pharmaceuticals Inc (IONS)

18 days ago - GuruFocus

Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc (Symbol: IONS) was identified as having a larger market cap than the smaller end...

26 days ago - Nasdaq

Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News

Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News

26 days ago - GuruFocus

Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News

Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News

26 days ago - GuruFocus

Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target Price Increase | IONS Stock News

Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target Price Increase | IONS Stock News

26 days ago - GuruFocus